Q2 2026 Acacia Research Corp Earnings Call Transcript
Key Points
- Acacia Research Corp (ACTG) delivered strong Q2 2026 results with total revenue of $114.6 million and adjusted EBITDA of $17.3 million, reflecting robust performance across its diversified business model.
- The company's intellectual property platform generated significant licensing revenue of $60.6 million, driven by a major settlement in its WiFi 6 portfolio, showcasing the platform's value creation potential.
- Benchmark, a key operating segment, achieved record revenue and strong free cash flow of $6.5 million, with successful drilling results and a promising development pipeline for future wells.
- Acacia Research Corp (ACTG) maintains a robust balance sheet with $334.6 million in cash, securities, and loans receivable, and no parent company debt, providing significant financial flexibility for future investments.
- The company successfully exited a public equity investment at an attractive return after an acquisition announcement, demonstrating its ability to identify undervalued opportunities and monetize them effectively.
- AMO Pharma's regulatory feedback from FDA, MHRA, and Health Canada for its lead candidate represents a positive milestone, potentially enhancing the value of Acacia's life sciences portfolio.
- Acacia Research Corp (ACTG) recorded a full writedown of its investment in Mycovia Pharmaceuticals due to liquidity issues and extended FDA timelines, highlighting the inherent risks in its life sciences portfolio.
- The intellectual property segment's licensing revenue is inherently episodic, leading to significant quarterly volatility and making it difficult to predict consistent earnings from this platform.
- Deflecto, a manufacturing segment, continues to face softer demand conditions, with adjusted EBITDA of only $1.1 million, indicating ongoing challenges in its end markets despite restructuring efforts.
- The company incurred $3.7 million in non-recurring legal expenses related to a legacy litigation matter, which negatively impacted EBITDA and underscores potential ongoing legal risks.
- GAAP net income was minimal at $47,000, reflecting the impact of impairments and other charges, which may concern investors focused on bottom-line profitability.
- The company's book value per share declined to $5.71 from $5.87 in the prior quarter, driven by the Mycovia writedown and parent company expenses, indicating a reduction in shareholder equity.
Okay.
Oh okay.
Good morning, everyone and welcome to Acacia Research Corporation's second quarter 2026 earnings conference.
My name is Holly, and I will be your conference facilitator today.
At this time, all participants are in a listen-only mode to prevent any background noise following management's prepared remarks, we will open the call for questions, please note that today's call is being recorded and is also being webcast through the investor relations section of Acacia Research's website, I would now like to turn a conference over to Elizabeth Chikonas of Kanye Communications.
Elizabeth, please go ahead.
Thank you, operator, joining today's caller, MJ McNulty, Acacia's Chief Executive Officer, and Michael Zambito, Acacia's Chief Financial Officer.
Before management begins its prepared remarks, I'd like to remind everyone that certain statements made during today's call constitute forward looking statements within the meaning of 5.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
